Wednesday, October 14, 2026

Micron's Capex Has Roughly Doubled in a Year and Its Cash Pile Has Grown 2.5x: What the AI Memory Squeeze Looks Like in the Filings

SEC-filed figures show Micron's capital spending nearly doubled in fiscal 2025 while its cost of revenue rose about 15%. Its cash more than doubled in a year. Analyst targets, supplier alliances and consolidation deals sit around those numbers, but the sources behind them vary a lot in reliability.

LM Salvado
LM Salvado

October 14, 2026

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Micron's Capex Has Roughly Doubled in a Year and Its Cash Pile Has Grown 2.5x: What the AI Memory Squeeze Looks Like in the Filings
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The money is moving faster than the costs

The clearest verified evidence that AI demand is straining the memory supply chain is in Micron Technology's SEC filings. Its capital expenditure, the money spent on factories and equipment, was $7.676 billion in fiscal 2023 and $8.386 billion in fiscal 2024.1 In fiscal 2025 it reached $15.857 billion.1 That is about 1.9 times the prior year, so the company spent in one year almost as much as the previous two years combined.1

The quarterly figures show the same pattern. First-quarter capex was $1.796 billion in fiscal 2024, $3.206 billion in fiscal 2025 and $5.389 billion in fiscal 2026.1 That is about three times the level of two years earlier.1

Cost of revenue, the direct cost of making what Micron sells, rose far more slowly. It was $16.956 billion in fiscal 2023, $19.498 billion in fiscal 2024 and $22.505 billion in fiscal 2025.1 That is a rise of about 15% in the latest year, against nearly 90% for capex.1 Quarter on quarter, cost of revenue was $5.361 billion in the first quarter of fiscal 2025 and $5.997 billion a year later. For the second quarter it was $5.090 billion, then $6.105 billion.1 Those are increases of about 12% and 20%.1

The gap matters for a plain reason. A company that spends this much more on building capacity than on producing goods is betting that demand will stay high for years. It is also spending ahead of the revenue that would pay for it. Our dossier has no revenue or profit figures for Micron, so we cannot say how much of the spending is already paid for by sales. We can say how the company has funded it: from a growing cash balance.

A balance sheet that keeps filling up

Micron's cash was $8.577 billion in the third quarter of fiscal 2023, then $7.594 billion in the same quarter of 2024 and $10.163 billion in 2025.1 In the third quarter of fiscal 2026 it stood at $24.995 billion.1 That is about 2.5 times the figure a year earlier, and it is up from $13.908 billion just one quarter before.1

Putting capex and cash side by side, Micron's fiscal 2025 capex of $15.857 billion was about 1.6 times its year-end cash of $9.642 billion.1 By the third quarter of fiscal 2026, the cash balance alone was more than the whole of fiscal 2025 capex.1 The company is building a cushion while it spends heavily. The dossier does not say where the extra cash came from, so we do not speculate on it.

This helps explain why buybacks are part of the story. Under CHIPS Act restrictions, our event record says Micron is technically eligible to restart stock buybacks, but analysts are not necessarily expecting an announcement.2 A buyback would mean the company spending cash to buy its own shares. Whether it does so is a choice between that and the building programme above.

The analyst view, and how much weight it deserves

The most quoted bullish signals come from one research firm. Lynx Equity Strategies rates Micron "a clear buy with anticipated upside of 33%" and says the same of Sandisk, with anticipated upside of 49%.3 These claims come from a Motley Fool article about ASML's 4% rise on the day.3 Our measured reliability for that source is low: only 22% of 18 checked claims held up.3 The sample is small, but treat the targets as one firm's opinion, not as verified data. A price target is a forecast, not a fact, and none of the SEC figures above depend on it.

Locking in supply: the alliances

If memory is scarce, the buyers try to secure it. Nvidia's Raj Mirpuri said the Nvidia–SK Hynix expansion "will include a co-develop opportunity for us on the next-generation SK Hynix AI memory, and this will help us secure a stable supply of HBM memory."4 HBM is the high-bandwidth memory used alongside AI processors. The same article says roughly $950 billion in new AI agreements were signed at a South Korea summit in San Francisco on July 24.4 We cannot put that figure in a familiar context from our data. The source is mid-range on our reliability measure, with 56% of 4,959 checked claims holding up.4 The $950 billion is therefore a reported headline total, not a verified one.

Moving data is the second bottleneck

The squeeze is not only about memory chips. It is also about moving data between them. Bull and Kalray announced on July 28 a collaboration on networking technology for AI and high-performance computing, including compatibility with Ultra Ethernet, a new open standard.5 Kalray's Éric Baissus said the agreement confirms the relevance of the company's technological vision.5

GlobalFoundries signed a letter of intent with the U.S. Department of Commerce for a $300 million award to accelerate silicon photonics, the optical technology that moves data using light.6 A letter of intent is not a final award. AMD's Mark Papermaster said: "As AI systems scale, moving data efficiently is as critical as increasing compute performance."6

Consolidation continues elsewhere in the sector. Skyworks and Qorvo have announced the expected leadership team for their combined company, effective once their pending transaction completes.7 Both press releases come from a source where only 32% of 2,928 checked claims held up.5,6 That is typical of company-issued announcements, which we can confirm were made but whose claims should be read as the company's own account.5,6

A small-cap look at the same boom

Solitron Devices is a tiny chip supplier, but its quarter shows how uneven a boom can be. Net sales rose 101% to about $5.44 million in its fiscal 2027 first quarter, from $2.70 million a year earlier.8 Net bookings fell 48% to $1.45 million, while backlog rose 28% to $23.34 million.8 Falling new orders next to a growing backlog is a mixed signal. The company says it expects sales to continue "at this level or greater for the remainder of the 2027 fiscal year."8 That is a company projection.

The efficiency angle: chips that waste less heat

Hannah Earley, cofounder and CTO of Vaire Computing, argues that waste heat is "a design choice," in the paraphrase of MIT Technology Review, which describes her approach as reversible computing.9 She says: "I want to tackle every part of how computers are built, and rethink it in these terms."9 The idea is early-stage. Our reliability measure for that source is 0% of 11 checked claims, a very small sample, and the piece is a profile and not a financial disclosure. Zeta, a marketing-software company, announced on October 8 that it has begun development of a specialised AIM chip with partners, in what it calls a capital-light approach.10 That is a company statement and we have no financial detail on it.

Insider selling, in context

Lattice Semiconductor's SVP of Strategy and Marketing, Esam Elashmawi, reported selling 16,773 shares at a weighted average price of $134.56 per share, about $2.3 million in total, according to an SEC Form 4 filing.11 One insider sale does not tell you much, since executives sell for many personal reasons. We mention it only because it is a verifiable, filed transaction in a sector where most of the bullish noise is not. The Motley Fool source carries the same low reliability score as above, so the original SEC filing is the better reference.11

What Via News's analysis suggests

Via News's narrative analysis groups these items under a single theme: AI demand is creating a chip and memory shortage that the data suggests could last 12 to 18 months, pushing consolidation, supplier alliances and specialised chip designs.12 It also lists growing regulatory and geopolitical friction, including FTC scrutiny of AI agents, OpenAI's copying accusations against Moonshot, Chinese espionage targeting AI experts and China's YMTC expanding NAND capacity.12 This is our analysis, not an external fact. The dossier gives no sourced detail on the shortage's length or on those friction points, so we do not weigh them further. The one part we can fully check is Micron's balance sheet, and it shows a company spending and saving at the same time.

As for whether you already own this exposure: the dossier does not say how much Micron or the other names make up of any index fund. If you hold a broad technology or semiconductor fund, check its holdings list directly.

What to watch

  • Whether Micron's capex keeps climbing faster than its cost of revenue. If cost of revenue starts to catch up, the spending is hitting production costs.
  • Whether Micron announces a buyback, and how the size of the cash pile changes next to capex.
  • Whether the GlobalFoundries letter of intent becomes a final award.
  • Whether Solitron's falling bookings reverse or its backlog is worked through as sales.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· July 28, 2026
    BULL ET KALRAY S'ASSOCIENT POUR DÉVELOPPER LA PROCHAINE GÉNÉRATION DE RÉSEAUX À HAUTE VITESSE POUR L'ÈRE DE L'IA
  2. [2]Press releaseGlobeNewswire· July 29, 2026
    GlobalFoundries signs letter of intent with the U.S. Department of Commerce for a $300 million award to accelerate U.S. silicon photonics leadership
  3. [3]News articleMotley Fool
    Lattice Semiconductor SVP Elashmawi Sells 16,773 Shares for $2.3 Million
  4. [4]News articleYahoo Finance· July 26, 2026
    Nvidia just locked down deal that changes AI race
  5. [5]News articleYahoo Finance· July 28, 2026
    Skyworks and Qorvo Announce Expected Leadership Team for Combined Company
  6. [6]Press releaseGlobeNewswire· July 13, 2026
    Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results
  7. [7]News articleCrunchbase News
    The IPO Window Is Closing. Here Are 8 Startups To Watch.
  8. [8]News articleMIT Technology Review
    This founder is teaching chips how to recycle (their energy)
  9. [9]News articleMotley Fool
    Why ASML Holding Stock Bumped 4% Higher Today
  10. [10]News articleYahoo Finance· October 4, 2026
    ASUS Googlebook 14 Now Available for Purchase in the United States
  11. [11]News articleYahoo Finance· September 30, 2026
    How Micron's earnings results could impact chip ETFs
  12. [12]News articleIEEE Spectrum
    IEEE Report Predicts Tech That Will Transform Lives
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com